Armistice Capital, LLC Biogen Inc. Transaction History

Armistice Capital, LLC

$7.69 Billion
Q2 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$212.02 - $267.71 $21.2 Million - $26.8 Million	-99,951 Reduced 49.98%	100,049 $21.6 Million
Q4 2023 Feb 13, 2024	SELL	$222.59 - $267.94 $17.1 Million - $20.6 Million	-76,788 Reduced 27.74%	200,000 $51.8 Million
Q3 2023 Nov 14, 2023	BUY	$253.3 - $285.89 $5.27 Million - $5.94 Million	20,788 Added 8.12%	276,788 $71.1 Million
Q2 2023 Aug 14, 2023	SELL	$275.25 - $318.06 $53.4 Million - $61.7 Million	-194,000 Reduced 43.11%	256,000 $72.9 Million
Q1 2023 May 15, 2023	BUY	$256.56 - $292.34 $12.8 Million - $14.6 Million	50,000 Added 12.5%	450,000 $125 Million
Q4 2022 Feb 14, 2023	BUY	$252.44 - $306.72 $44.4 Million - $54 Million	176,000 Added 78.57%	400,000 $111 Million
Q3 2022 Nov 14, 2022	SELL	$194.69 - $268.46 $2.34 Million - $3.22 Million	-12,000 Reduced 5.08%	224,000 $59.8 Million
Q2 2022 Aug 15, 2022	SELL	$187.54 - $223.02 $63 Million - $74.9 Million	-336,000 Reduced 58.74%	236,000 $48.1 Million
Q1 2022 May 16, 2022	BUY	$193.77 - $244.14 $21.7 Million - $27.3 Million	112,000 Added 24.35%	572,000 $120 Million
Q4 2021 Feb 14, 2022	BUY	$223.92 - $287.77 $19.7 Million - $25.3 Million	88,000 Added 23.66%	460,000 $110 Million
Q3 2021 Nov 15, 2021	BUY	$282.99 - $369.05 $1.13 Million - $1.48 Million	4,000 Added 1.09%	372,000 $105 Million
Q2 2021 Aug 16, 2021	BUY	$259.0 - $414.71 $20.7 Million - $33.2 Million	80,000 Added 27.78%	368,000 $127 Million
Q1 2021 May 17, 2021	BUY	$242.95 - $284.63 $7.29 Million - $8.54 Million	30,000 Added 11.63%	288,000 $80.6 Million
Q4 2020 Feb 16, 2021	BUY	$236.26 - $355.63 $37.3 Million - $56.2 Million	158,000 Added 158.0%	258,000 $63.2 Million
Q3 2020 Nov 16, 2020	SELL	$264.77 - $305.71 $30.7 Million - $35.5 Million	-116,000 Reduced 53.7%	100,000 $28.4 Million
Q2 2020 Aug 14, 2020	BUY	$258.66 - $342.55 $40.9 Million - $54.1 Million	158,000 Added 272.41%	216,000 $57.8 Million
Q1 2020 May 15, 2020	SELL	$268.85 - $341.04 $18.8 Million - $23.9 Million	-70,000 Reduced 54.69%	58,000 $18.4 Million
Q4 2019 Feb 14, 2020	SELL	$220.06 - $304.07 $4.4 Million - $6.08 Million	-20,000 Reduced 13.51%	128,000 $38 Million
Q3 2019 Nov 14, 2019	BUY	$217.44 - $243.88 $26.1 Million - $29.3 Million	120,000 Added 428.57%	148,000 $34.5 Million
Q2 2019 Aug 14, 2019	SELL	$219.29 - $241.72 $26.8 Million - $29.5 Million	-122,000 Reduced 81.33%	28,000 $6.55 Million
Q1 2019 May 15, 2019	BUY	$216.71 - $338.96 $32.5 Million - $50.8 Million	150,000 New	150,000 $35.5 Million

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

Vanguard Group Inc Valley Forge, PA

16.6M
Shares

$2.88 Billion
0.08% of portfolio
Primecap Management CO Pasadena, CA

16.3M
Shares

$2.84 Billion
2.78% of portfolio
Black Rock Inc. New York, NY

14.5M
Shares

$2.53 Billion
0.08% of portfolio
State Street Corp Boston, MA

7.1M
Shares

$1.23 Billion
0.07% of portfolio
T. Rowe Price Investment Management, Inc. Baltimore, MD

5.68M
Shares

$987 Million
0.83% of portfolio

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Armistice Capital, LLC with notifications on news.

Account